NCT06048302招募中1 期
A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Plasma Pharmacokinetics and Safety of Obicetrapib in Participants With Moderate Hepatic Impairment Relative to Participants With Normal Hepatic Function
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Area under the curve from dosing time to infinity (AUC (0-inf)) for obicetrapib
研究概览
简要总结
To investigate the safety and pharmacokinetics in patients with moderate hepatic impairment compared to healthy participants after a single oral dose of obicetrapib (10 mg).
详细描述
This is a Phase 1, open-label, single-dose, parallel-group study to evaluate the plasma PK and safety of obicetrapib in participants with moderate hepatic impairment relative to participants with normal hepatic function. The purpose of the study is to investigate the effect of moderate hepatic impairment on obicetrapib PK and safety in otherwise healthy participants after a single oral 10 mg dose of obicetrapib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A male or a female of non-childbearing potential.
- •Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin (β-hCG) pregnancy test at the Screening Visit.
- •Body mass index (BMI) of 17.5 to 42 kg/m2; with a total body weight >50 kg (110 lb).
- •Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- •Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- •Cohort 1: Meet the criteria for Class B (moderate hepatic impairment) of the modified CPC. A diagnosis of hepatic dysfunction due to hepatocellular disease (and not secondary to any acute ongoing hepatocellular process) documented by medical history, physical examination (PE), liver biopsy, hepatic ultrasound, computerized tomography scan, or magnetic resonance imaging.
- •Cohort 2: Will only enroll healthy volunteers with no hepatic impairment. "Healthy" is defined as no clinically relevant abnormalities identified by a detailed medical history, complete PE (including blood pressure [BP] and pulse rate measurement), 12-lead ECG or clinical laboratory tests performed during Screening.
排除标准
- •Any condition possibly affecting drug absorption (e.g., gastrectomy). Uncomplicated cholecystectomy is allowed.
- •History of or current positive results for human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV) or hepatitis C virus (HCV), including hepatitis B surface antigen (HbsAg) or hepatitis C Virus antibody (HCVAb).
- •Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the Investigator's judgment, make the participant inappropriate for participation in the study.
- •Participants with an estimated glomerular filtration rate (eGFR) value of ≤30 mL/min/1.73 m2, based on the 2021 Chronic Kidney Disease Epidemiology Collaboration equation during Screening. A single repeat assessment is permitted to assess eligibility, if needed.
- •Previous administration of drugs or supplements known to be strong inducers or inhibitors of CYP3A4 within 7 days of planned dosing of obicetrapib on Day
- •Concurrent use of drugs or supplements that are known substrates of CYP3A that have narrow therapeutic indices (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl including transdermal patch, pimozide, quinidine, sirolimus, tacrolimus) within 12 days prior to planned dosing of obicetrapib on Day
- •Participants on oral contraceptives and hormonal based contraceptives including implantable, intrauterine, intravaginal, transdermal or injectable form.
- •Previous administration of an investigational drug within 30 days (or as determined by the local requirement) or within 5 half-lives of that investigational drug, prior to planned dosing of obicetrapib on Day
- •Known hypersensitivity to obicetrapib or its excipients.
- •A positive urine drug test. Participants with moderate hepatic impairment (Cohort 1) will be eligible to participate if their urine drug test is positive with a drug for a prescribed condition that is not expected to interfere with the PK of obicetrapib. Positive urine drug tests for tetrahydrocannabinol (THC) will be allowed as long as the volunteer agrees to abstain from ingesting any THC-containing products for the duration of the study (including Out patient visits up to Day 28).
- •Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to planned dosing of obicetrapib on Day
- •History of sensitivity to heparin or a history of heparin-induced thrombocytopenia.
- •Unwilling or unable to comply with the criteria in the Lifestyle considerations listed in the protocol.
研究组 & 干预措施
Active Comparitor: Subjects with Moderate Hepatic Impairment
Active Comparator
8 patients with hepatic impairment of moderate Child Pugh Category
干预措施: Obicetrapib (Drug)
Active Comparator: Healthy Subjects
Other
Healthy volunteers will be matched with impaired hepatic function patients
干预措施: Obicetrapib (Drug)
结局指标
主要结局
Area under the curve from dosing time to infinity (AUC (0-inf)) for obicetrapib
时间窗: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168
Blood samples collected
Area under curve from dosing time to last measurement (AUC (0-t)) for obicetrapib
时间窗: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168
Blood Sample Collected
Observed maximum plasma concentration (Cmax) for Obicetrapib
时间窗: 0 (pre-dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168
Blood Sample Collected
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control GroupPharmacokinetics of MDV3100Healthy SubjectsKidney DiseasesNCT01901133Astellas Pharma Europe B.V.33
已完成
1 期
PK Study of Sotagliflozin in Subjects With Hepatic ImpairmentHepatic ImpairmentHealthyNCT02471274Lexicon Pharmaceuticals32
已完成
1 期
Pharmacokinetics of Mitiperstat in Participants With Hepatic ImpairmentHepatic ImpairmentNCT05751759AstraZeneca31
已完成
1 期
Pharmacokinetics of ZSP1273 in Participants With Hepatic ImpairmentHepatic ImpairmentPharmacokineticsNCT05856513Guangdong Raynovent Biotech Co., Ltd24
已完成
1 期
Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic ImpairmentHepatic ImpairmentNCT06161259Guangdong Raynovent Biotech Co., Ltd24